Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.4% | +28.0% |
| SANG, HONG | 1 | 54.7% | +62.6% |
| ABBOTT, KODYE LEE | 1 | 57.7% | +64.7% |
| SHELDEN, BION A | 1 | 22.0% | +18.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17689845 | MOBILE PROCESSING UNIT AND LABORATORIES | SHELDEN, BION A | 104d overdue |
| 17759647 | PROCESS AND SYSTEM FOR ACELLULAR THERAPY | ABBOTT, KODYE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17689845 | MOBILE PROCESSING UNIT AND LABORATORIES | SHELDEN, BION A | 104d overdue |
| 18727113 | NASAL ANTI-CANCER THERAPIES | GILL, RACHEL B | — |
| 18583721 | CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE AND TRANSMEMBRANE DOMAIN AND USES THEREOF | SANG, HONG | — |
| 17759647 | PROCESS AND SYSTEM FOR ACELLULAR THERAPY | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1634 | 1 |
| 3685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727113 | NASAL ANTI-CANCER THERAPIES | GILL, RACHEL B | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18583721 | CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE AND TRANSMEMBRANE DOMAIN AND USES THEREOF | SANG, HONG | 1646 | DP | Non-Final OA | — | Pending | Feb 21, 2024 |
| 17759647 | PROCESS AND SYSTEM FOR ACELLULAR THERAPY | ABBOTT, KODYE LEE | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17689845 | MOBILE PROCESSING UNIT AND LABORATORIES | SHELDEN, BION A | 3685 | §103 | Non-Final OA | 104d overdue | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial